In Brief: Bard completes Impra acquisition

Bard completes Impra acquisition: Bard pays $143.2 mil. for all common stock of Impra, a manufacturer of PTFE vascular grafts with $48.8 mil. in fiscal 1996 (ended June 30) sales. The deal, announced in August ("The Gray Sheet" Aug. 12, I&W-1), is the largest in Bard's history, the company says...